EMAIL THIS PAGE TO A FRIEND

Current topics in microbiology and immunology

Sphingosine-1 phosphate and central nervous system.


PMID 24728597

Abstract

The development of fingolimod, an unselective functional antagonist of the interactions between sphingosine 1 phosphate (S1P) and sphingosine 1 phosphate receptors (S1PRs), as the first oral therapy for multiple sclerosis (MS) has been a milestone. The parallel intensive research on the role of S1P, sphingosine kinases, and the five known S1PRs, their tissue distribution and expression in physiological and pathological conditions have led to a wide range of interesting findings. The initial focus of this research in the context of developing fingolimod as a treatment of MS has been on its immunological effects. The wide distribution and important roles of sphingosine, its metabolites, and their receptors in the central nervous system (CNS) in general, in myelin, and in all cell types of this organ have spurred interest to examine S1P and its five receptors in the brain as well. The present review will concentrate on the latter area and give a brief overview of what is known about S1P/S1PR interactions in the CNS in physiological and pathological conditions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

S9666
Sphingosine 1-phosphate, ≥95%, powder
C18H38NO5P
73914
Sphingosine 1-phosphate, ≥98.0% (TLC)
C18H38NO5P